- Home
- ABL vs RLAY Comparison
ABL vs RLAY Comparison
Compare ABL & RLAY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ABL
- RLAY
- Stock Information
- Founded
- ABL 2004
- RLAY 2015
- Country
- ABL United States
- RLAY United States
- Employees
- ABL N/A
- RLAY N/A
- Industry
- ABL Investment Managers
- RLAY Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- ABL Finance
- RLAY Health Care
- Exchange
- ABL Nasdaq
- RLAY Nasdaq
- Market Cap
- ABL 602.4M
- RLAY 610.3M
- IPO Year
- ABL N/A
- RLAY 2020
- Fundamental
- Price
- ABL $6.88
- RLAY $3.52
- Analyst Decision
- ABL Strong Buy
- RLAY Strong Buy
- Analyst Count
- ABL 3
- RLAY 12
- Target Price
- ABL $12.83
- RLAY $18.45
- AVG Volume (30 Days)
- ABL 671.9K
- RLAY 1.9M
- Earning Date
- ABL 08-07-2025
- RLAY 08-07-2025
- Dividend Yield
- ABL N/A
- RLAY N/A
- EPS Growth
- ABL N/A
- RLAY N/A
- EPS
- ABL N/A
- RLAY N/A
- Revenue
- ABL $161,724,466.00
- RLAY $8,355,000.00
- Revenue This Year
- ABL $77.22
- RLAY $31.55
- Revenue Next Year
- ABL $29.93
- RLAY N/A
- P/E Ratio
- ABL N/A
- RLAY N/A
- Revenue Growth
- ABL 69.56
- RLAY N/A
- 52 Week Low
- ABL $4.60
- RLAY $1.78
- 52 Week High
- ABL $10.95
- RLAY $10.72
- Technical
- Relative Strength Index (RSI)
- ABL 74.27
- RLAY 51.45
- Support Level
- ABL $6.23
- RLAY $3.31
- Resistance Level
- ABL $7.03
- RLAY $3.72
- Average True Range (ATR)
- ABL 0.30
- RLAY 0.18
- MACD
- ABL 0.09
- RLAY 0.01
- Stochastic Oscillator
- ABL 90.62
- RLAY 71.65
About ABL Abacus Life Inc.
Abacus Global Management Inc is a financial services company specializing in alternative asset management, data-driven wealth solutions, technology innovations, and institutional services. The Company organizes its business into five reportable segments Active Management, Originations, Asset Management, Portfolio Servicing, and Technology Services. Its operations are confined to the United States.
About RLAY Relay Therapeutics Inc.
Relay Therapeutics Inc is a clinical-stage precision medicine company transforming the drug discovery process by combining leading-edge computational and experimental technologies with the goal of bringing life-changing therapies to patients. the Dynamo platform integrates an array of leading-edge computational and experimental approaches designed to drug-protein targets that have previously been intractable or inadequately addressed. The company is advancing a pipeline of medicine candidates to address targets in precision oncology and genetic disease, including product candidates, RLY-4008, RLY-2608, and GDC-1971 (formerly known as RLY-1971).